sur Nyxoah SA. (isin : BE0974358906)
Nyxoah Receives FDA Approval and Reports Q2 2025 Results
Nyxoah SA, a medical technology company, has secured FDA approval for its Genio® system, commencing its commercial launch in the U.S. This marks a significant step for the company, emphasizing their innovative approach to treating Obstructive Sleep Apnea (OSA) through neuromodulation. The Genio system stands out as the first bilateral hypoglossal neurostimulation therapy in the U.S., highlighting its unique design and efficacy.
Financially, Nyxoah reported a revenue of €1.3 million for Q2 2025, a rise from €0.8 million in 2024, reflecting a 74% growth. Despite this, the company recorded an operating loss of €19.9 million, influenced by increased expenses in research, development, and commercial activities. Nyxoah's cash reserves saw a decrease to €43.0 million by June 30, 2025.
The company's recent strides emphasize its commitment to expanding its presence and solutions within the healthcare sector.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Nyxoah SA.